Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WeSMA: Long-term Follow-up Study of Risdiplam in SMA
NCT05232929Phase 4Completed
- Sponsor
- Genentech
- Start
- Mar 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Genentech. Started Mar 2022; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05232929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232929.